Healthcare / BiotechnologyTaiwan
$82.80
+0.10 (+0.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-81.5M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.3%
↓Gross Margin
63.0%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+27.9%
FCF CAGR
—
FCF margin
-322.3%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.1M · net income $-114.8M · FCF $-97.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.1M | $30.1M | $31.9M | $24.6M | $14.4M |
| Net Income | $-114.8M | $-114.8M | $-93.1M | $-84.1M | $-91.2M |
| EBITDA | $-92.9M | $-92.9M | $-64.0M | $-56.3M | $-65.6M |
| EPS | — | — | -1.62 | -1.56 | -2.20 |
| Gross Margin | 63.0% | 63.0% | 64.5% | 72.8% | 56.9% |
| Operating Margin | -432.4% | -432.4% | -322.8% | -391.6% | -639.8% |
| Net Margin | -381.5% | -381.5% | -291.9% | -342.1% | -633.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.10 | 0.12 | 0.20 |
| Current Ratio | 40.56 | 40.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-97.0M | $-97.0M | $-67.2M | $-81.5M | $-78.2M |
| Returns | |||||
| ROE | -13.3% | -13.3% | -13.6% | -14.1% | -27.3% |
| Valuation | |||||
| P/B | 6.09 | 6.09 | 5.78 | 7.50 | 3.92 |
| Growth & Yield | |||||
| Revenue Growth | -5.6% | -5.6% | 29.7% | 70.8% | — |
| EPS Growth | — | — | -3.8% | 29.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+28.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.62 → n/d
Residual
+28.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.